Iovance Biotherapeutics Inc (Iovance) is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer immunotherapies based on tumour-infiltrating lymphocyte (TIL) technology for patients with solid tumors. TIL therapies use a patient’s own immune cells harvested from a tumor and expanded ex vivo to create an individualized, autologous cell therapy designed to recognize diverse tumor-specific mutations and help address mechanisms of tumor immune escape.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Iovance’s R&D activities focus on the development of immunotherapies for the treatment of metastatic melanoma, squamous cell carcinoma of the head and neck, cervical carcinoma, and other solid tumor indications. The company is conducting multicenter trials, including TIL monotherapies and TIL cell therapy in combination with standard care therapies. Ongoing registrational trials are being conducted to support a supplementary BLA for lifileucel in frontline advanced melanoma and advanced non-small cell lung cancer. Additionally, the company is advancing next-generation TIL therapies through genetic modifications using TALEN (e.g., IOV-4001), cytokine-tethered IL-12 TIL candidate IOV-5001 (IND-enabling; pre-IND with FDA planned), and new regimens including IOV-3001, a modified IL-2 analog with an IND accepted for phase 1/2, aiming to enhance potency, safety, and efficacy. The company operates a research laboratory in Tampa, Florida, the US. In FY2025, the company spent US$300.2 million on its R&D activities. As of December 2025, the company employed 775 personnel in R&D activities. Iovance owns several granted patents and pending patent applications in the fields of TIL therapy, MIL therapy, PBL therapy, TIL, MIL, and PBL manufacturing processes and expansion methods. As of December 2025, the company owned over 330 granted or allowed US and international patents and patent applications pertaining to Amtagvi and other TIL-related technologies, and over 90 US patents related to TIL cell therapy. Iovance seeks to work in partnerships with universities, government, academic research institutions, and corporate partners to develop and commercialize its products. Its research partnerships include the National Institute of Health/ National Cancer Institute; Moffitt Cancer Center; MD Anderson Cancer Center; and Yale University, among others.